Clinical

Articles

Data from a phase 1b trial of the combination of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma display safety and early efficacy. 

Frontline Regorafenib Plus Pembrolizumab Reveals Antitumor Activity in HCC 

Adding toripalimab and hepatic arterial infusion chemotherapy to lenvatinib yielded robust, durable responses for patients with advanced hepatocellular carcinoma.

Toripalimab and HAIC Plus Lenvatinib Produced Durable Responses in Advanced HCC

Objective response data from a phase 2 trial supported the FDA’s decision to grant infigratinib accelerated approval to treat patients with certain a certain type of cholangiocarcinoma. 

Infigratinib Granted Accelerated Approval for FGFR2+ Cholangiocarcinoma

Adjuvant nivolumab for resected esophageal or gastroesophageal junction cancer was granted full approval by the FDA based on statistically significant improvements in disease-free survival over placebo in a phase 3 trial.

FDA Grants Approval to Nivolumab as Adjuvant Treatment of Resected Esophageal/GEJ Cancer

According to an economic evaluation, the use of atezolizumab plus bevacizumab is not cost effective versus sorafenib for the treatment of hepatocellular carcinoma when considering life-years gained and willingness-to-pay thresholds. 

Analysis Correlates Cost of Therapy With Improvement in Outcomes for Patients With HCC

In patients with gastrointestinal cancers, factors such as younger age and comorbidities, among others, were significantly associated with a greater likelihood of sleep disturbance. 


Greater Sleep Disturbance Associated With External Factors in Patients With GI Cancers

Based on response data from a randomized phase 3 trial, the FDA granted accelerated approval to pembrolizumab plus trastuzumab and chemotherapy for the treatment of HER2-positive gastric tumors. 

FDA Grants Accelerated Approval to Pembrolizumab/Trastuzumab Combination for HER2+ Gastric/GEJ Cancers

Based on results of a phase 3 study, the IDH1-targeted agent ivosidenib will be considered by the FDA as therapy for cholangiocarcinoma following prior treatment. 

Ivosidenib Earns Priority Review for IDH1-Mutated Cholangiocarcinoma After Prior Therapy

By a close decision, the FDA’s Oncologic Drugs Advisory Committee voted against upholding the accelerated approval of nivolumab monotherapy to treat patients with hepatocellular carcinoma following sorafenib. 

FDA Committee Does Not Support Maintaining Accelerated Approval of Nivolumab for Advanced HCC 

Young women with gastrointestinal cancers who received the FOLFIRI or FOLFOX chemotherapy regimens experienced a benefit in terms of reduced nausea and vomiting with the combination of aprepitant plus palonosetron and dexamethasone.

Gastrointestinal Cancer | Topics